Figure 2.
Impact of tocilizumab on acute GVHD. For moderate-severe aGVHD (II-IV), cumulative hazard plots for all patients over +100 days (A), for VUD patients over +100 days (B), for all patients over +180 days (C), and for VUD patients for +180 days (D).

Impact of tocilizumab on acute GVHD. For moderate-severe aGVHD (II-IV), cumulative hazard plots for all patients over +100 days (A), for VUD patients over +100 days (B), for all patients over +180 days (C), and for VUD patients for +180 days (D).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal